Blueprint Medicines (NASDAQ:BPMC) Stock Price Down 6.1%
Blueprint Medicines Corp (NASDAQ:BPMC)’s share price fell 6.1% during trading on Monday . The company traded as low as $72.61 and last traded at $73.17, 829,289 shares traded hands during trading. An increase of 80% from the average session volume of 460,212 shares. The stock had previously closed at $77.96.
A number of research firms have weighed in on BPMC. Canaccord Genuity increased their target price on Blueprint Medicines from $105.00 to $120.00 and gave the company a “buy” rating in a report on Friday, August 2nd. BidaskClub cut Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Deutsche Bank initiated coverage on Blueprint Medicines in a research note on Thursday, July 18th. They set a “buy” rating and a $110.00 price target for the company. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Blueprint Medicines in a research report on Monday. Finally, Robert W. Baird initiated coverage on shares of Blueprint Medicines in a research report on Thursday, July 18th. They set an “outperform” rating and a $120.00 price target for the company. Two research analysts have rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Blueprint Medicines presently has an average rating of “Buy” and an average price target of $107.60.
The firm has a 50 day moving average price of $84.83 and a 200 day moving average price of $84.70. The stock has a market capitalization of $3.59 billion, a PE ratio of -14.25 and a beta of 1.64. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 0.16.
In other Blueprint Medicines news, Director George Demetri sold 1,136 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $98.50, for a total value of $111,896.00. Following the completion of the transaction, the director now directly owns 5,303 shares in the company, valued at $522,345.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ariel Hurley sold 1,405 shares of the stock in a transaction on Monday, June 17th. The stock was sold at an average price of $98.22, for a total transaction of $137,999.10. Following the completion of the sale, the insider now directly owns 830 shares of the company’s stock, valued at $81,522.60. The disclosure for this sale can be found here. Insiders sold 108,888 shares of company stock worth $9,752,015 in the last ninety days. Corporate insiders own 4.02% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Nomura Holdings Inc. purchased a new stake in Blueprint Medicines in the 2nd quarter worth $1,209,000. BlackRock Inc. lifted its position in shares of Blueprint Medicines by 20.9% in the second quarter. BlackRock Inc. now owns 4,109,222 shares of the biotechnology company’s stock valued at $387,621,000 after acquiring an additional 710,147 shares in the last quarter. Chartwell Investment Partners LLC boosted its stake in shares of Blueprint Medicines by 21.6% in the second quarter. Chartwell Investment Partners LLC now owns 23,775 shares of the biotechnology company’s stock worth $2,243,000 after acquiring an additional 4,219 shares during the period. International Biotechnology Trust PLC bought a new position in shares of Blueprint Medicines in the second quarter worth about $1,604,000. Finally, Ladenburg Thalmann Financial Services Inc. grew its position in shares of Blueprint Medicines by 62.8% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,097 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 423 shares in the last quarter.
About Blueprint Medicines (NASDAQ:BPMC)
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Further Reading: How mutual funds make money
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.